Mesoblast Limited (ASX:MSB)
Market Cap | 3.07B |
Revenue (ttm) | 26.23M |
Net Income (ttm) | -155.80M |
Shares Out | 1.28B |
EPS (ttm) | -0.13 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 5,551,700 |
Average Volume | 5,098,189 |
Open | 2.430 |
Previous Close | 2.490 |
Day's Range | 2.360 - 2.450 |
52-Week Range | 1.020 - 3.370 |
Beta | 1.17 |
RSI | 54.44 |
Earnings Date | Nov 18, 2025 |
About Mesoblast
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc... [Read more]
Financial Performance
In 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.
Financial numbers in USD Financial StatementsNews

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic ce...

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercia...
Mesoblast enters option to issue $50M convertible notes

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into con...

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript
Mesoblast Limited (NASDAQ:MESO) Q4 2025 Earnings Conference Call August 28, 2025 6:30 PM ET Company Participants Andrew Chaponnel - Interim Chief Finance Officer Marcelo Santoro - Chief Commercial Of...
Mesoblast Limited 2025 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Mesoblast Limited in conjunction with their 2025 Q4 earnings call.
Full Year 2025 Mesoblast Ltd Earnings Presentation Transcript
Full Year 2025 Mesoblast Ltd Earnings Presentation Transcript
Mesoblast (MESO) Sees Revenue Surge in FY25 with Ryoncil's FDA Approval
Mesoblast (MESO) Sees Revenue Surge in FY25 with Ryoncil's FDA Approval

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
Financial Results and Operational Update for the Full Year Ended June 30, 2025 Financial Results and Operational Update for the Full Year Ended June 30, 2025
Examining the Future: Mesoblast's Earnings Outlook
Mesoblast (NASDAQ: MESO) will release its quarterly earnings report on Thursday, 2025-08-28. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Mesoblast to report a...
Mesoblast shares soar 35pc on strong cell therapy sales data
The biotech says sales of its first commercial therapy, Ryoncil, were $20 million in the quarter ending June 30.
Successful Commercial Launch of Ryoncil®
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sa...

Successful Commercial Launch of Ryoncil®
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales...
ASX 200 LIVE: ASX 200 at record; Mesoblast soars 30pc on sales boost
Shares trade strongly after BHP posts record year for iron ore and copper. Mesoblast reports strong sales in flagship. Atlas Arteria fails in 40 per cent toll hike bid. Follow live.
Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade)

Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining over 250 points on Tuesday. Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Tuesday's session after the company announced align...
Mesoblast, FDA agree on marketing application for cell therapy

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor
On Monday, Mesoblast Ltd . (NASDAQ: MESO) announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexleme...

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor
On Monday, Mesoblast Ltd. MESO announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexlemestrocel-L) f...

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States...

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum w...

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years ...
Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials
Mesoblast reports Q3 results

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent...